Tag: COVID-19
10 Things You Should Consider When Planning a COVID-19 Clinical Drug Trial
This blog asks and answers 10 critical drug development questions whether you have a new molecular entity or are repurposing a drug already in clinical use.
Local Therapies for the Global COVID-19 Pandemic
Henri Merdjan explains why topical drug formulations (e.g. intranasal and/or oral) could be valuable as a therapeutic option for COVID-19 patients.
Certara & DMTC Announce Collaboration to Study Using Chloroquine in Healthcare Workers at Risk for COVID-19
Certara applying expertise in clinical pharmacology, innovation and collaboration to accelerate potential prophylaxis for COVID-19
Applying decision analysis to drug development for COVID-19 & future pandemics
This blog discusses how decision analysis approaches can help drug developers to better decisions under multiple criteria and uncertainty.
Considerations for Management of Clinical Trials and Regulatory Filing Strategy in Light of COVID-19
COVID-19 has the potential to negatively impact critical activities such as patient recruitment, patient safety and ensuring data integrity. Thus, clinical developers should review their planned regulatory filing strategies to determine if modifications are required. Attend this webinar to learn mitigation strategies and best practices that you can begin implementing now. 講演者Demetrius Carter, SVP … Continued
サターラが新型コロナウイルスの治療薬開発を支援するCOVID-19 Pharmacologyオンライン・リソース・センターを創設
Funded by the Bill & Melinda Gates Foundation, the online Center helps accelerate therapeutics for COVID-19 by integrating clinical pharmacology, innovation and collaboration
